Cargando…
Clinical outcomes in individuals hospitalized with SARS-CoV-2 Delta variant (B.1.617.2) who had been vaccinated with Covishield (ChAdOx1) and Covaxin (BBV-152)
BACKGROUND: Covishield (ChAdOx) and Covaxin (BBV-152) are the mainstream vaccines against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) used in India and a few other countries. OBJECTIVE: To assess the clinical outcomes of patients hospitalized with coronavirus disease 2019 (COVID-19)...
Autores principales: | Munigela, Apoorva, Sowpati, Divya Tej, M, Sasikala, Banu, Sofia, Siva, Archana Bharadwaj, V, Jagadeesh Kumar, Nutalapati, Chandrasekhar, Vishnubhotla, Ravikanth, Kulkarni, Anand, Mukherjee, Payel, Zaveri, Lamuk, Rao, G.V., Tallapaka, Karthik Bharadwaj, Nageshwar Reddy, D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9444261/ https://www.ncbi.nlm.nih.gov/pubmed/36090517 http://dx.doi.org/10.1016/j.ijregi.2022.08.016 |
Ejemplares similares
-
Inactivated vaccine Covaxin/BBV152: A systematic review
por: Ahmed, Tousief Irshad, et al.
Publicado: (2022) -
Pityriasis Rosea Following Covaxin (BBV152) Vaccination for COVID-19
por: Singh, Bhabani S. T. P., et al.
Publicado: (2022) -
Evidence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Reinfection Without Mutations in the Spike Protein
por: Kulkarni, Onkar, et al.
Publicado: (2021) -
Immunogenicity and safety of homologous and heterologous booster vaccination of ChAdOx1 nCoV-19 (COVISHIELD™) and BBV152 (COVAXIN®): a non-inferiority phase 4, participant and observer-blinded, randomised study
por: Rose, Winsley, et al.
Publicado: (2023) -
Effectiveness of BBV152/Covaxin and AZD1222/Covishield vaccines against severe COVID-19 and B.1.617.2/Delta variant in India, 2021: a multi-centric hospital-based case-control study
por: Bhatnagar, Tarun, et al.
Publicado: (2022)